Immune dysfunction in the presence of residual splenic tissue

R C COHEN AND A FERRANTE

Department of Paediatric Surgery and Department of Paediatrics, University of Adelaide, Adelaide Children's Hospital, Australia

SUMMARY Immunological function was examined in children who had undergone splenectomy, in 8 for trauma, and in 11 for haematologic/oncologic reasons. Particular emphasis was placed on the effects of residual splenic tissue on immune function. Children in the elective group had no evidence of splenosis but 6 of the 8 trauma patients showed residual splenic activity. A general trend indicated that immunological dysfunction was associated with the presence of residual splenic tissue. Three patients with significant post-traumatic splenosis showed low IgM levels, one also had a low IgG level and another a low IgA and impaired lymphocyte response to mitogens. The trauma patients with little or no splenic tissue had normal immune functions. Immunological abnormalities were found in 8 of the 11 haematologic/oncologic patients with no splenosis suggesting the abnormalities were possibly due to the primary disease. In contrast to the popular belief that splenosis confers protection against overwhelming sepsis, the present findings suggest that patients with residual splenic tissue are at a greater risk of infection because of a lower level of immune response.

The spleen plays an important role in host resistance to infection. Among the many properties of splenic tissue are the elaboration of specific immune responses and clearance of micro-organisms, and old or injured red blood cells from the circulation. Removal of the spleen either for trauma or for haematologic indications is well known to be associated with an increased incidence of morbidity due to sepsis. The risk of this is lowest after splenectomy for trauma and it has been suggested that the common occurrence of post-traumatic splenosis may provide protection against overwhelming sepsis in such children. However, clinical evidence of morbidity and mortality from sepsis in patients with well documented evidence of splenosis would seem to cast doubt on the protective nature of residual splenic tissue. In the present study we compared the immune function of patients with and without residual splenic tissue after splenectomy for either traumatic or haematologic indications.

Patients and methods

The study comprised 18 children who underwent splenectomy at Adelaide Children's Hospital for either trauma or haematologic indications and one boy, aged 9 years, who had a complete splenic avulsion injury diagnosed on nuclear scan and treated non-operatively in 1980. Seven patients (4 boys and 3 girls) aged 8 to 13 years underwent splenectomy during the period 1966-75 for blunt splenic trauma. At laparotomy all had either lacerated or transected spleens. At the time of restudy their ages ranged from 10 to 24 years. The remaining 11 patients (6 boys and 5 girls) aged 3 to 13 years were also studied. These patients underwent elective splenectomy during the period 1970-81 for haematologic indications (3 for thalassaemia major, 4 for hereditary spherocytosis, 2 for idiopathic thrombocytopenic purpura, and 2 for staging of Hodgkin's disease). The ages of these patients at restudy were 6 to 32 years. The 2 patients with Hodgkin's disease were chosen because they had completed their course of treatment at least 3 years previously. One of these was stage IA treated with local radiotherapy, the other was stage IVA treated with radiotherapy and chemotherapy. Each thalassaemic patient had a routine whole blood transfusion one month before being investigated.

Methods for determining residual splenic tissue

Two methods were used to detect residual splenic tissue: $^{99m}$Tc phytate liver/spleen scan and assessing the percentage of circulating 'pitted' red cells by...
interference phase microscopical examination. Venous blood was taken from all patients just before performing a nuclear liver/spleen scan, so that only one venepuncture was required. Blood was taken from 10 normal control children with no known haematologic, splenic, or hepatic disease. The blood was treated according to the method of Holroyde et al. One drop of blood was immediately placed into 0.5 ml of phosphate buffered glutaraldehyde solution, pH 7.4. This was examined as a wet preparation with oil objective lens on an Olympus interference phase contrast microscope using Nomarski optics (×1250); 2000 cells were individually scanned on two separate specimens from each patient to determine the percentage of ‘pitted’ red cells.

The liver/spleen scans were carried out using a Searle Pho Gamma IV Gamma camera, fitted with either a low-energy all-purpose, or diverging collimator as appropriate to the patient’s size. Each patient was injected intravenously with 70 μCi/kg technetium phytate. Images were obtained about 10 minutes after injection when the maximum liver/spleen uptake of the radionuclide occurred.

Routine liver/spleen views were performed including anterior, right lateral, posterior, left posterior oblique, and left anterior oblique positions. Anterior views of the pelvis and abdomen were also obtained to identify the presence and site of possible splenoses. Each scan took about 30 minutes.

In one case, where difficulty was encountered in visually separating residual splenic tissue from the left lobe of the liver, scanning was done using autologous, technetium labelled, heat affected red cells.

We found it difficult to assign accurate volumes to the residual splenic tissue. Using simple geometrical calculations we looked at a range of normal spleens and found that the calculations yielded volumes which correlated well with spleen weights from necropsy studies. In most of our cases, the residual spleen was clearly spherical which made calculation easy and probably reasonably accurate. With other shapes of residual spleen we used the geometrical models which seemed appropriate. We related our calculated volumes to the volume we regarded as normal for the patient’s age, and expressed the volume of residual splenic tissue as a percentage of normal.

Immune function studies

Mononuclear leucocytes (MNL) and polymorphonuclear leucocytes (PMNL) were prepared using the method of Ferrante and Thong. Briefly, heparinised blood samples were layered on to Ficoll-Hypaque medium density 1.114 g/ml. After centrifugation for 30 min, the MNL and PMNL were recovered as distinct cellular fractions at the interface and between the interface and the sedimented erythrocytes respectively. The cell populations both of >95% purity were washed three times in medium 199.

The percentage of T- and B-cells in the MNL fraction was enumerated by the E-rosette technique and binding of FITC-labelled goat anti-immunoglobulin. Lymphocyte transformation studies were performed as previously described. Briefly, to each well of a microtitre plate was seeded 2 × 10⁶ lymphocytes (MNL) in 0.1 ml RPMI 1640 medium, supplemented with 10% heat-inactivated fetal calf serum. Lymphocytes were stimulated by addition of either 0.1 ml phytohaemagglutinin (10 μg/ml), Concanavalin A (12.5 μg/ml), or pokeweed mitogen (50 μg/ml), reconstituted in the above medium. Cultures were incubated at 37°C for 72 hours in an atmosphere of 5% CO₂/air and high humidity, and pulsed with 1-0 μCi (³H) thymidine 6 hours before harvest. The samples were counted in a Packard Tricarb liquid scintillation spectrophotometer. The results were expressed as stimulation index (SI); in which

\[
SI = \frac{\text{cells + mitogens (counts/min)}}{\text{cells only (counts/min)}}
\]

PMNL chemotaxis was performed by the agarose technique. Torulopsis glabrata activated human serum was used as a source of chemotactic agent. Leucocyte iodium was carried out by the semi-automated method; PMNL bactericidal and fungicidal activity was measured using Staphylococcus aureus and T. glabrata.

Serum level of immunoglobulin classes (IgA, IgG, IgM) and complement components (C3, C4) were measured by the radial immunodiffusion technique (Behring, West Germany). Total haemolytic complement was measured by determining the amount of complement source needed to produce lysis of 50% of opsonised sheep red blood cells and expressed as C₅b ₃b ₃b units/ml.

Patients were tested twice, 4 months apart, and results presented as the mean. During the performance of each test, blood from healthy individuals was included as a control.

Results

The proportion of ‘pitted’ red blood cells in 10 normal control patients was less than 1%. None of the 11 children whose spleens had been removed electively had evidence of residual splenic activity on nuclear scan; they had an average of 45% ‘pitted’
Immune dysfunction in the presence of residual splenic tissue

red blood cells (range 33–57%). Six of the 8 trauma patients had nuclear scan evidence of residual splenic tissue ranging from 2 to 70% of normal splenic volume (Figs 1–2). However, only 4 of the 8 patients showed splenic activity when assessed by percentage of 'pitted' red cells with values of 0.4, 0.6, 10, and 15%. There was no association between the degree of splenosis and the severity of the splenic injury.

Two patients with about 2 and 7% of normal splenic volume on scan were within the range of the asplenic patients when assessed by percentage of 'pitted' red cells, with values of 54 and 40% respectively. As the liver/spleen scan was a more sensitive indicator of splenosis the results from this technique were used to determine the relationship between splenosis and immune function.

All patients splenectomised for trauma showed normal levels of T- and B-cells, while 5 of the 11 patients who had undergone elective splenectomy had low T-cell numbers (Fig. 3). The B-cell numbers in the elective splenectomy group were within the normal range.

The patient with approximately 70% normal splenic volume showed greatly reduced mitogen-induced lymphocyte response to phytohaemagglutinin, pokeweed mitogen, and Concanavalin A with an SI less than 5, the lower limit of the normal response. In addition, IgA (0.53 g/l) (normal range = 0.8–4.8 g/l) and IgM (0.3 g/l) (normal range = 0.5–2.0 g/l) were below the normal ranges. This patient developed severe bronchopneumonia 4 years after splenectomy and has also had more frequent minor

---

**Fig. 1** Left anterior oblique liver/spleen scan of a 21-year-old patient 10 years after splenectomy for traumatic laceration. Residual splenic tissue (arrowed) represents about 20% normal splenic volume: 15% of the RBCs were 'pitted'.

**Fig. 2** Left posterior oblique liver/spleen scan of 9-year-old boy 1 year after avulsion, the residual splenic tissue (arrowed) represents about 45% normal splenic volume: 0.6% of the RBCs were 'pitted'.

**Fig. 3** T cell numbers in patients splenectomised for trauma (○) or haematologic/oncologic indications: thalassaemia (■), ITP (▲), spherocytosis (○), Hodgkin's disease (●). (—) represents normal range.
upper respiratory tract infections since splenectomy. The other patients in the trauma group demonstrated normal lymphocyte responsiveness to mitogen. Levels of IgM were depressed in all 3 patients who demonstrated the most residual splenic tissue with values of a similar order to the treated Hodgkin’s disease patients (Fig. 4). The patient with 45% normal splenic volume also showed a low level of IgG (6-6 g/l); normal range = 7-20–19-20 g/l. The remaining patients in both groups did not demonstrate immunoglobulin levels below the normal range.

There was a general depression of lymphocyte responsiveness to mitogen stimulation in patients in the elective group compared with the trauma group. Seven of the 11 patients demonstrated a lymphocyte SI less than 10 in response to at least one of the mitogens and 3 patients (2 thalassaemia, 1 spherocytosis, 1 splenectomy) had an SI less than 5, the lower limit of the normal response. Two patients with thalassaemia developed bronchopneumonia, one had 7 episodes of bronchopneumonia in the 4 years after splenectomy, the other also developed S. aureus sepsicaemia 5 years after splenectomy. Both Hodgkin’s disease patients developed herpes zoster infections.

Complement levels (C3, C4, and CH50) and PMNL functions were normal in both groups of patients.

Discussion

The increased risk of fulminant and fatal sepsis in splenectomised individuals at all ages, in particular infants and children, has now been established by large population studies. Individuals who undergo splenectomy for haematologic and oncologic conditions have a greatly increased mortality and morbidity owing to sepsis. These clinical observations are substantiated by our finding that 8 (73%) of the 11 children splenectomised for medical reasons and without evidence of residual splenic tissue, had at least one reduced immune parameter. In contrast, patients splenectomised for trauma without residual splenic tissue had normal immunological function, suggesting that the immune abnormalities in the elective group were possibly due to their primary disease.

Experiments on animals have demonstrated the immunological benefits of partial splenectomy compared with total splenectomy. Such findings have suggested that patients may benefit from splenic autotransplants at the time of splenectomy or splenic artery ligation, and that residual splenic tissue may constitute a protective mechanism against overwhelming sepsis. However, there are reports in children and adults of severe and even lethal post-splenectomy sepsicaemia despite the presence of splenic tissue seen on isotope scan and at necropsy. Furthermore, while some investigators have shown that splenosis in experimental animals resulted in reduction of mortality rate, others found that splenosis did not enhance blood stream clearance of pneumococcus, which is the causative organism in half the cases of overwhelming post-splenectomy infection. Splenosis is a common occurrence after splenectomy for trauma and this finding is supported by the present study. Clinical and experimental findings suggest that residual splenic tissue may not be protective. Indeed, in our study three patients with approximately 70%, 45%, and 20% of normal splenic volume demonstrated abnormal immune function.

Mouse experiments have demonstrated an important function of the spleen is to generate suppressor and amplifier lymphocytes. These two functions are important in co-ordinating antibody responses. Possibly, in patients with a critical mass of residual splenic tissue the balance between suppressor and amplifier cell function is disturbed so that the suppressor activity predominates. This may account for or contribute to the abnormal immune function observed in our patients. The reduced immunological reactivity may predispose the individual to bacterial infections or it may be responsible for increased susceptibility to viral infections, which may subsequently compromise the host to convert an asymptomatic carrier state into a fulminant pneumococcaemia.

Autotransplantation of splenic tissue or splenic artery ligation as methods of management of the ruptured spleen have been suggested on the basis of
Immune dysfunction in the presence of residual splenic tissue

animal experiments in order to preserve some of the immunological function of the spleen. The data from our study suggested that information based on these animal studies may not be translated into the human situation.

We thank Mr B S Douglas, Professor G M Maxwell, Professor Y H Thong, Dr K Cheney, Dr J Savage, and Dr I Toogood for help and encouragement and the consultant surgeons of the Adelaide Children's Hospital for access to their patients.

References


Correspondence to Dr R C Cohen, Department of Surgery, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia.

Received 19 January 1982
Immune dysfunction in the presence of residual splenic tissue.
R C Cohen and A Ferrante

Arch Dis Child 1982 57: 523-527
doi: 10.1136/adc.57.7.523

Updated information and services can be found at: http://adc.bmj.com/content/57/7/523

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/